Biomed Pharmacother 1(108):952962 Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB (2008) The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, Liraglutide
Type 2 diabetes is an established risk factor for cognitive decline and dementia, with insulin resistance and chronic hyperglycaemia potentially contributing to neuronal damage
PATHWAYS: Inhibits TNF alpha [ 11 , 12 ], which is otherwise associated with cancer in general [ 205 ], Melanoma [ 49 ]
This benefit appeared independent of weight loss, suggesting direct cardiovascular protective effects from GLP-1 receptor activation
Fadilah NIM, Isa ILM, Zaman WSWK, Tabata Y, Fauzi MB
Copper ions alone (not the peptide) have demonstrated up to 90% inhibition of type 1 5-alpha reductase in laboratory settings